

TRABECTEDIN

BRAND NAME	YONDELIS
DRUG CLASS	Cytotoxic antineoplastic, alkylating agent
AVAILABILITY	Vial contains 0.25 mg or 1 mg of trabectedin. Also contains sucrose, monobasic potassium phosphate, phosphoric acid and potassium hydroxide. ¹
WARNING	<p>Cytotoxic.¹ Strict handling precautions are required. Trabectedin is a vesicant, extravasation is a medical emergency and causes severe complications e.g. tissue damage, ulceration, prolonged healing time.^{1,2,4} Hypersensitivity and anaphylactic reactions may occur. Resuscitation facilities must be readily available.¹</p>
PREPARATION	<p>In a cytotoxic drug safety cabinet: Reconstitute the 0.25 mg vial with 5 mL of water for injections and the 1 mg vial with 20 mL of water for injections to make a concentration of 0.05 mg/mL. Shake to dissolve.¹ The solution is clear and colourless to pale yellow.¹ Dilute the dose in at least 50 mL of a compatible fluid. The maximum concentration is 0.03 mg/mL.¹</p>
STABILITY	<p>Vial: store at 2 to 8 °C. Do not freeze.¹ When prepared by pharmacy under aseptic conditions: Reconstituted solution: stable for 24 hours below 25 °C or at 2 to 8 °C.¹ Infusion solution: stable for 30 hours below 25 °C.¹</p>
ADMINISTRATION	
IM injection	Not recommended
SUBCUT injection	Not recommended
IV injection	Not recommended
IV infusion	Give as a continuous infusion into a central venous access device over 24 hours. ^{1,3} Use a 0.2 micrometre inline PES filter. ^{1,3}
COMPATIBILITY	Glucose 5% ¹ , sodium chloride 0.9% ¹
INCOMPATIBILITY	Do not mix with other medicines
SPECIAL NOTES	<p>Monitor the injection site. Stop the infusion if there are signs of extravasation and take immediate action.^{1,2,4} Trabectedin is moderately emetogenic.^{1,4} Check your local guidelines for premedication requirements.</p>

REFERENCES

1. Product information. Available from www.tga.gov.au. Accessed 12/01/2022.
2. Jones RL, Maki RG, Patel SR, Wang G, McGowan TA, Shalaby WS, et al. Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: clinical considerations for outpatient administration of trabectedin. *Cancer* 2019; 125: 4435-41.
3. Protocol: Soft tissue sarcoma advanced or metastatic trabectedin [v1 June 2021]. eviQ [internet]. Sydney: Cancer Institute NSW. Available from www.eviq.org.au. Accessed 12/01/2022.
4. Clinical resource: Extravasation Management [v4 2019]. eviQ [internet]. Sydney: Cancer Institute NSW. Available from www.eviq.org.au. Accessed 12/01/2022.
5. Clinical resource: Prevention of antineoplastic induced nausea and vomiting [v5 May 2021]. eviQ [internet]. Sydney: Cancer Institute NSW. Available from www.eviq.org.au. Accessed 08/02/2022.

